<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6618298</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">31334108</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6618298</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.3389/fonc.2019.00567</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Clinical parameters.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1</label><caption><p>Clinical parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Items</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Pre-RT group (<italic>n</italic> = 56)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Post-RT group (<italic>n</italic> = 37)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Post-CCRT group (<italic>n</italic> = 108)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>P-</italic>value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Sex</bold>, <italic><bold>n</bold></italic></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">43 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (36.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">13 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (9.5)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (years)</bold>,<break/><bold>mean</bold><bold>±</bold><bold>SD</bold></td><td valign="top" align="center" rowspan="1" colspan="1">47.0 ± 9.0</td><td valign="top" align="center" rowspan="1" colspan="1">48.5 ± 10.1</td><td valign="top" align="center" rowspan="1" colspan="1">45.5 ± 7.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>KPS score</bold><break/><bold>(median</bold><bold>±</bold><bold>IQR, range)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">90 ± 0, 80–90</td><td valign="top" align="center" rowspan="1" colspan="1">90 ± 0, 80–90</td><td valign="top" align="center" rowspan="1" colspan="1">90 ± 0, 80–90</td><td valign="top" align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Main side of NPC</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">17 (8.4)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Right, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">22 (10.9)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (9.0)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (24.9)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bilateral, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">17 (8.4)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (5.5)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (18.9)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Clinical staging</bold><bold>(</bold><xref rid="B28" ref-type="bibr"><bold>28</bold></xref><bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">I/II, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">14 (7.0)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (11.4)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.01<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">III/IV, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">42 (20.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (42.3)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>RT technology</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IMRT, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">28 (19.3)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (59.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2D-CRT, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">9 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (15.2)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Maximum dosage of RT for temporal lobes (Gy)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">62.6 ± 7.8<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">66.0 ± 10.3<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Right</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">64.6 ± 7.0<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">67.5 ± 8.1<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Time intervals between</bold><break/><bold>RT and fMRI and sMRI</bold><break/><bold>examinations (month)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">20.9 ± 25.4</td><td valign="top" align="center" rowspan="1" colspan="1">16.9 ± 23.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>RE in the follow-up</bold>, <italic><bold>n</bold></italic></td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">1/37 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">22/108 (20.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><p><italic>SD, standard deviation; KPS, Karnofsky Performance Status; IQR, interquartile range; UICC, International Union against Cancer; AJCC, American Joint Committee on Cancer; RT, radiation therapy; IMRT, intensity-modulated radiation therapy; 2D-CRT, conventional two-dimensional radiotherapy; fMRI, functional MRI; sMRI, structural MRI; RE, radiation encephalopathy. (1) Data in parentheses are percentages; (2) The superscripts a and b denote data loss in 5 and 9 subjects respectively; (3) The demographic characteristics of the subjects are presented as the mean and SD with a normal distribution, median, and IQR with a non-normal distribution, or distribution of the frequency with qualitative data</italic>.</p><fn id="TN1"><label>*</label><p><italic>P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Clinical parameters.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Items</th><th valign="top" align="center">Pre-RT group (n = 56)</th><th valign="top" align="center">Post-RT group (n = 37)</th><th valign="top" align="center">Post-CCRT group (n = 108)</th><th valign="top" align="center">P-value</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5">Sex, n</td></tr><tr><td valign="top" align="left">Male</td><td valign="top" align="center">43 (21.4)</td><td valign="top" align="center">29 (14.4)</td><td valign="top" align="center">74 (36.8)</td><td valign="top" align="center">0.59</td></tr><tr><td valign="top" align="left">Female</td><td valign="top" align="center">13 (6.5)</td><td valign="top" align="center">8 (4.0)</td><td valign="top" align="center">19 (9.5)</td><td/></tr><tr><td valign="top" align="left">Age (years),mean±SD</td><td valign="top" align="center">47.0 ± 9.0</td><td valign="top" align="center">48.5 ± 10.1</td><td valign="top" align="center">45.5 ± 7.8</td><td valign="top" align="center">0.17</td></tr><tr><td valign="top" align="left">KPS score(median±IQR, range)</td><td valign="top" align="center">90 ± 0, 80–90</td><td valign="top" align="center">90 ± 0, 80–90</td><td valign="top" align="center">90 ± 0, 80–90</td><td valign="top" align="center">0.59</td></tr><tr><td valign="top" align="left" colspan="5">Main side of NPC</td></tr><tr><td valign="top" align="left">Left, n</td><td valign="top" align="center">17 (8.4)</td><td valign="top" align="center">8 (4.0)</td><td valign="top" align="center">20 (10.0)</td><td valign="top" align="center">0.51</td></tr><tr><td valign="top" align="left">Right, n</td><td valign="top" align="center">22 (10.9)</td><td valign="top" align="center">18 (9.0)</td><td valign="top" align="center">50 (24.9)</td><td/></tr><tr><td valign="top" align="left">Bilateral, n</td><td valign="top" align="center">17 (8.4)</td><td valign="top" align="center">11 (5.5)</td><td valign="top" align="center">38 (18.9)</td><td/></tr><tr><td valign="top" align="left" colspan="5">Clinical staging(???)</td></tr><tr><td valign="top" align="left">I/II, n</td><td valign="top" align="center">14 (7.0)</td><td valign="top" align="center">29 (14.4)</td><td valign="top" align="center">23 (11.4)</td><td valign="top" align="center">&lt;0.01???</td></tr><tr><td valign="top" align="left">III/IV, n</td><td valign="top" align="center">42 (20.9)</td><td valign="top" align="center">8 (4.0)</td><td valign="top" align="center">85 (42.3)</td><td/></tr><tr><td valign="top" align="left" colspan="5">RT technology</td></tr><tr><td valign="top" align="left">IMRT, n</td><td valign="top" align="center">NA</td><td valign="top" align="center">28 (19.3)</td><td valign="top" align="center">86 (59.3)</td><td valign="top" align="center">0.61</td></tr><tr><td valign="top" align="left">2D-CRT, n</td><td valign="top" align="center">NA</td><td valign="top" align="center">9 (6.2)</td><td valign="top" align="center">22 (15.2)</td><td/></tr><tr><td valign="top" align="left" colspan="5">Maximum dosage of RT for temporal lobes (Gy)</td></tr><tr><td valign="top" align="left">Left</td><td valign="top" align="center">NA</td><td valign="top" align="center">62.6 ± 7.8a</td><td valign="top" align="center">66.0 ± 10.3b</td><td valign="top" align="center">0.14</td></tr><tr><td valign="top" align="left">Right</td><td valign="top" align="center">NA</td><td valign="top" align="center">64.6 ± 7.0a</td><td valign="top" align="center">67.5 ± 8.1b</td><td valign="top" align="center">0.13</td></tr><tr><td valign="top" align="left">Time intervals betweenRT and fMRI and sMRIexaminations (month)</td><td valign="top" align="center">NA</td><td valign="top" align="center">20.9 ± 25.4</td><td valign="top" align="center">16.9 ± 23.8</td><td valign="top" align="center">0.39</td></tr><tr><td valign="top" align="left">RE in the follow-up, n</td><td valign="top" align="center">NA</td><td valign="top" align="center">1/37 (2.7)</td><td valign="top" align="center">22/108 (20.4)</td><td valign="top" align="center">0.01???</td></tr></tbody></table></div>SD, standard deviation; KPS, Karnofsky Performance Status; IQR, interquartile range; UICC, International Union against Cancer; AJCC, American Joint Committee on Cancer; RT, radiation therapy; IMRT, intensity-modulated radiation therapy; 2D-CRT, conventional two-dimensional radiotherapy; fMRI, functional MRI; sMRI, structural MRI; RE, radiation encephalopathy. (1) Data in parentheses are percentages; (2) The superscripts a and b denote data loss in 5 and 9 subjects respectively; (3) The demographic characteristics of the subjects are presented as the mean and SD with a normal distribution, median, and IQR with a non-normal distribution, or distribution of the frequency with qualitative data.*P &lt; 0.05.</transformed-table></extracted-table></extracted-tables-set>